Beyond Trade: How the EU–India FTA reshapes life-sciences industry

New Delhi: For decades, the relationship between India and the European Union in healthcare was transactional. India supplied affordable generics; Europe set global regulatory standards. One manufactured, the other regulated. One delivered volume, the other delivered innovation.

The EU–India Free Trade Agreement (FTA) finally concluded after nearly 20 years of negotiations. It promises to rewrite that script, not as a simple tariff pact but as a platform for collaboration, especially in pharma, biotech, and medtech.

“We delivered the mother of all deals… This historic agreement will drive trade, investment and innovation while strengthening our strategic relationship,” said Prime Minister Narendra Modi, calling the pact the “mother of all deals” and “a new blueprint for shared prosperity.”

European Commission President Ursula von der Leyen echoed the sentiment: “Prime Minister, distinguished friend, we did it. We delivered the mother of all deals. We are creating a market of two billion people… a tale of two giants, the world’s second and fourth largest economies.”

Collectively, the deal represents nearly 25% of global GDP and one-third of global trade, making it one of the most consequential trade agreements of this era.

Pharma: From Cost Advantage to Strategic Partner

India’s pharmaceutical industry has long been Europe’s silent backbone. Nearly one in four generic medicines consumed in the EU has an Indian origin, even if the label rarely says so. Antibiotics, cardiovascular drugs, oncology injectables—India has supplied them all, quietly and efficiently.

Yet the relationship has been asymmetrical. Indian firms faced stringent regulatory audits, delayed approvals, and pricing pressures, while European innovators enjoyed stronger intellectual property protection and higher margins.

The EU–India FTA aims to rebalance this equation.

For Indian pharma companies, mutual recognition of Good Manufacturing Practices (GMP), faster regulatory pathways, and reduced non-tariff barriers could mean something transformative: predictability. That predictability is crucial as Indian firms move beyond generics into complex formulations, biosimilars, and specialty injectables.

European pharma, on the other hand, sees India less as a low-cost supplier and more as a strategic hedge. With geopolitical disruptions, supply chain shocks, and overdependence on limited manufacturing geographies, Europe is rethinking resilience. India—scale-ready, science-driven, and increasingly compliant—is emerging as a natural partner.

As per Suresh Nair, Partner, Indirect Tax, EY India, the EU–India FTA provides substantial benefits for the pharmaceutical and medical devices sectors, subject to phased implementation and final ratification details.

“The EU will eliminate tariffs of up to 11% on pharmaceuticals and reduce tariffs on approximately 90% of medical  devices from up to 27.5% to zero. The agreement strengthens regulatory cooperation, simplifies compliance procedures, and enhances intellectual property protections, improving the competitiveness of Indian exporters in this sector. EU firms gain improved access to India’s fast growing market for high value medical technologies. Overall, the FTA is expected to significantly expand bilateral market access and contribute to growth in high skill employment and manufacturing across both regions, while ongoing monitoring of non-tariff barriers and compliance requirements will help address potential challenges,” said Nair.

Namit Joshi, Chairman – Pharmexcil believes that for the pharmaceutical sector, the EU–India FTA delivers structural competitiveness. “Near-zero tariff access significantly strengthens the position of Indian formulations, APIs, and value-added medicines in the EU, a development that is particularly consequential for India’s pharma MSMEs, many of whom possess strong quality capabilities but face cost and access barriers in highly regulated markets. Reduced tariffs and smoother market entry will directly enhance their ability to scale exports, invest in compliance, and integrate into European supply chains.”

“Crucially, this agreement enables stable, long-term, and predictable pharmaceutical trade, benefiting European healthcare systems and consumers through improved affordability, continuity, and security of supply, supported by India’s high-quality and reliable manufacturing base. Equally important is the agreement’s balanced approach to intellectual property, which reaffirms TRIPS-aligned protections while safeguarding India’s strengths in generics and public health, thereby providing regulatory certainty and confidence for MSMEs as well as large manufacturers,” added Joshi.

The FTA could also lower barriers to cross-border clinical trials, harmonize data standards, and enable joint research funding mechanisms. For Indian biotech startups, access to European research networks, Horizon-style grants, and advanced regulatory science could accelerate global credibility. For European biotechs, India offers faster trials, diverse patient populations, and cost-efficient development pathways.

Dr. Saurabh Arora, Managing Director, Auriga Research feels that while FTA is going to be a huge opportunity, India needs to really improve quality infrastructure besides proactive steps by the government.

“It will be right from education on quality, training the manpower, up-skilling to deliver quality products and also creating quality testing and R&D infrastructure. At the same time, because of duty-free access between both the markets, we expect that medicines should definitely become more affordable. India imports almost 90% of medical devices and a large proportion of them originate from the European Union. Also, we import a lot of chemicals, starting materials and active pharmaceutical ingredients which will get cheaper, so finally the products will also get cheaper. India still imports some medicines also as finished forms from the EU and obviously those will also become cheaper. So overall there is going to be a positive impact for the consumers and we will have access to more cutting-edge medical device products and pharmaceutical products at a cheaper price,” said Dr Arora.

MedTech: Bridging Precision and Access

Europe is home to some of the world’s most sophisticated medtech companies: precision imaging, robotic surgery, implantable devices, digital diagnostics. India, by contrast, represents one of the fastest-growing medtech markets globally, driven by rising chronic disease, expanding insurance coverage, and a massive unmet need beyond metro cities.

Yet access remains uneven. High-end European devices are often priced out of reach, while Indian manufacturers struggle with fragmented regulations and limited acceptance in EU markets.

An FTA that harmonizes standards, simplifies conformity assessments, and encourages local manufacturing could change this equation. European firms could manufacture or assemble in India for global markets, while Indian medtech companies—many now innovating frugally in diagnostics, wearables, and point-of-care devices—could finally enter Europe with credibility.

Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) is hopeful that the EU–India FTA  would open a new chapter in healthcare cooperation, where success will be measured not only in GDP, but in lives improved and saved.

“If the fine print is in line with the announcements made, this FTA will enable India to strengthen its role as a reliable, innovation-driven partner by expanding exports of medical textiles, surgical instruments and disposables which India specializes in. European companies in India are hoping to benefit from lower duties, stronger participation in public procurement, and greater incentives for local manufacturing and R&D. Most importantly for patients, any eventual tariff reductions on medical devices should help improve affordability and access to advanced therapies, making this agreement a potential example of how ethical and equitable trade can reinforce health systems on both sides,” Choudary added further.

As per Bhargav Kotadia, Co-Chair, FICCI Medical Devices Committee & MD & CEO Sahajanand Medical Technologies Ltd (SMT), India has already emerged as a credible and reliable trading partner for the EU, particularly in cardiac implants and vascular devices.

“For the MedTech industry, the FTA presents a significant opportunity to build upon the EU-India strategic partnership by enhancing collaboration in technology sharing, strengthening health security, and expanding strategic cooperation on pressing global health challenges. This agreement can act as a catalyst for co-innovation, sustainable manufacturing, and making high-quality, affordable healthcare technologies accessible to a broader global population,” said Kotadia.

Dr Rajiv Chhibber, Joint Forum Coordinator, Association of Indian Medical Devices (AIMED) believes that EU–India FTA comes at a strategically important time, as Europe looks to diversify partnerships beyond US & China and deepen economic and diplomatic engagement with India.

“While the detailed contours of the agreement are awaited, it is clearly an industry friendly framework that will strengthen economic integration between both regions. In the life sciences, Pharmaceuticals and medical devices sector, India has already established itself as a trusted partner for the EU with growing acceptance across European markets. For the MedTech industry, the FTA offers a strong opportunity to further enhance the EU–India strategic partnership through greater technology collaboration, improved health security, and closer cooperation on shared global health priorities,” commented Dr Chhibber.

Dr. Vishwa Srivastava, CEO – APAC, SS Innovations International Inc. opined, “The proposed reduction in EU tariffs on industrial and medical equipment is a significant and timely step that can accelerate the global competitiveness of Indian MedTech innovation. For companies like SS Innovations, which are developing advanced, Made-in-India surgical robotic systems, lower tariff barriers open new opportunities to scale exports, improve price competitiveness, and strengthen India’s position as a trusted global manufacturing hub. This policy move not only supports trade efficiency but also reinforces the growing acceptance of high-quality Indian medical technologies in regulated international markets such as the EU.”

Outlook

While the outlook is positive but none of this will be frictionless.

Intellectual property remains the most sensitive fault line. Europe seeks stronger data exclusivity and patent protections; India remains wary of anything that could compromise access to affordable medicines. Regulatory convergence, too, will require trust—earned through transparency, not imposed through checklists. Labour mobility, recognition of professional qualifications, and visa regimes for scientists and engineers remain unresolved but critical. Innovation does not travel well when people do not.

And yet, the tone has shifted. This FTA is being negotiated in a world where health security is national security, and collaboration is no longer optional.

The EU–India FTA, viewed through the prism of pharma, biotech, and medtech, is less about trade volumes and more about intent. It signals a move away from a buyer–seller relationship toward co-creation.

For India, it is a chance to step fully into its role as a global life sciences leader—not just the pharmacy of the world, but its laboratory and factory floor combined. For Europe, it is an opportunity to anchor innovation in resilience, affordability, and scale.